Beam Therapeutics
Beam Therapeutics is seeking a senior leader to guide the development and implementation of potency assays and analytical methods for its in‑vivo and ex‑vivo gene editing programs. The VP will oversee assay strategy from IND through BLA, collaborate with CMC, regulatory, and quality teams, and drive risk‑based decision making across the product lifecycle.
Headquarters
Cambridge, Massachusetts, United States
Company Size
501-1000 employees
Founded
2017
Beam Therapeutics is a clinical-stage biotechnology company based in Cambridge, MA, pioneering precision genetic medicines using its proprietary base editing platform to make precise single‑base DNA changes without creating double‑strand breaks. The company advances both in vivo and ex vivo programs across hematology, rare genetic diseases, and oncology, moving several candidates toward clinical development. Beam combines engineered editors, delivery technologies, and extensive safety profiling to create durable, potentially one‑time treatments and partners with academic and industry collaborators to accelerate translation.
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
10 hours ago
Beam Therapeutics (BEAM) Leverages New Financing And IP Control Is Its Gene-Editing Edge Strengthening?
3 days ago
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Beam Therapeutics.
229% above the average for this role
After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate
2 weeks ago
Cell Biologist and Assay Developer
Abiologics
Cell Biologist and Assay Developer
Abiologics
Senior / Principal Associate Scientist
Strand Therapeutics
Senior Scientist I, Analytical Development, Biologics CMC
Exelixis
Director, Regulatory Sciences
Regeneron Pharmaceuticals
Senior Scientist, Bioanalytical Sciences (Innate Immunity, Ligand Binding Assays & Flow Cytometry)
Flagship Pioneering, Inc.